A new pediatric protocol for rapid desensitization to monoclonal antibodies

Silvia Maria Elena Caimmi, Davide Caimmi, Sara Riscassi, Gian Luigi Marseglia

Research output: Contribution to journalArticlepeer-review


Monoclonal antibodies are important therapeutic tools, but their usefulness may be limited when patients experience acute hypersensitivity reactions. Patients reporting a history of adverse allergic reaction are likely to discontinue their therapeutic protocol or be switched to an alternative drug, which is sometimes less effective than that originally prescribed. Drug desensitization has proven to be a highly effective strategy to readminister a drug in a patient who has experienced a hypersensitivity reaction. It involves forcing the patient's immune system to accept and tolerate the allergen. Nevertheless, such a procedure is still empiric for monoclonal antibodies and not common in the pediatric population. The aim of our study is to demonstrate the clinical success of a new protocol of rapid desensitization to infliximab in a pediatric patient affected by ulcerative colitis, who developed an anaphylaxis to the drug. We used a protocol of rapid desensitization consisting of 13 steps, with the first being 1/1,000,000 of the cumulative and total dose. Such a protocol has proven to be able to induce a temporary tolerance to infliximab, allowing the patient to achieve complete control of his disease.

Original languageEnglish
Pages (from-to)214-218
Number of pages5
JournalInternational Archives of Allergy and Immunology
Issue number3
Publication statusPublished - Jan 21 2014


  • Drug desensitization
  • Hypersensitivity reactions
  • Infliximab
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)


Dive into the research topics of 'A new pediatric protocol for rapid desensitization to monoclonal antibodies'. Together they form a unique fingerprint.

Cite this